We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×

Site maintenance planned for October 25th. Click here for further details

Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Journal of Comparative Effectiveness Research
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Published Online:https://doi.org/10.2217/14622416.7.3.387

Chronic fatigue syndrome (CFS) is characterized by persistent or relapsing fatigue that is not alleviated by rest, causes substantial reduction in activities and is accompanied by a variety of symptoms. Its unknown etiology may reflect that CFS is heterogeneous. Latent class analyses of symptoms and physiological systems were used to delineate subgroups within a population-based sample of fatigued and nonfatigued subjects [1]. This study examined whether genetic differences underlie the individual subgroups of the latent class solution. Polymorphisms in 11 candidate genes related to both hypothalamic–pituitary–adrenal (HPA) axis function and mood-related neurotransmitter systems were evaluated by comparing each of the five ill classes (Class 1, n = 33; Class 3, n = 22; Class 4, n = 22; Class 5, n = 17; Class 6, n = 11) of fatigued subjects with subjects defined as well (Class 2, n = 35). Of the five classes of subjects with unexplained fatigue, three classes were distinguished by gene polymorphsims involved in either HPA axis function or neurotransmitter systems, including proopiomelanocortin (POMC), nuclear receptor subfamily 3, group C, member 1 (NR3C1), monoamine oxidase A (MAOA), monoamine oxidase B (MAOB), and tryptophan hydroxylase 2 (TPH2). These data support the hypothesis that medically unexplained chronic fatigue is heterogeneous and presents preliminary evidence of the genetic mechanisms underlying some of the putative conditions.

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

  • Vollmer-Conna U, Aslakson E, White PD: An empirical delineation of the heterogeneity of chronic unexplained fatigue. Pharmacogenomics7(3), 355–364 (2006).• Describes chronic fatigue syndrome (CFS) heterogeneity upon which this paper is based.LinkGoogle Scholar
  • Fukuda K, Straus SE, Hickie I et al.: The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med.121, 953–959 (1994).Crossref, Medline, CASGoogle Scholar
  • Reeves WC, Lloyd A, Vernon SD et al.: Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv. Res.3, 25 (2003).Crossref, MedlineGoogle Scholar
  • Hickie I, Lloyd A, Hadzi-Pavlovic D, Parker G, Bird K, Wakefield A: Can the chronic fatigue syndrome be defined by distinct clinical features? Psychol. Med. 25, 925–935 (1995). Google Scholar
  • Stouten B: Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv. Res.5, 37 (2005).Crossref, MedlineGoogle Scholar
  • Sullivan PF, Pedersen NL, Jacks A, Evengard B: Chronic fatigue in a population sample: definitions and heterogeneity. Psychol. Med.35(9), 1337–1348 (2005). Crossref, MedlineGoogle Scholar
  • Vernon SD, Reeves WC: The challenge of integrating disparate high-content data: Epidemiologic, clinical and laboratory data collected during an in-hospital study of chronic fatigue syndrome. Pharmacogenomics7(3), 345–354 (2006).• Describes recruitment and clinical assessment of subjects used in this study.Google Scholar
  • Gerrity TR, Bates J, Bell DS et al.: Chronic fatigue syndrome: what role does the autonomic nervous system play in the pathophysiology of this complex illness? Neuroimmunomodulation10(3), 134–141 (2002). Google Scholar
  • Freeman R: The chronic fatigue syndrome is a disease of the autonomic nervous system. Sometimes. Clin. Auton. Res.12, 231–233 (2002).Crossref, MedlineGoogle Scholar
  • 10  Cleare AJ: The neuroendocrinology of chronic fatigue syndrome. Endocr. Rev.24, 236–252 (2003).Crossref, Medline, CASGoogle Scholar
  • 11  Cleare AJ: The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol. Metab.15(2), 55–59 (2004). Crossref, Medline, CASGoogle Scholar
  • 12  Hoefgen B, Schulze TG, Ohlraun S et al.: The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol. Psychiatry57, 247–251 (2005).Crossref, Medline, CASGoogle Scholar
  • 13  Westfall PH, Young SS: Resampling-based Multiple Testing. John Wiley & Sons, Inc., New York, USA (1993).Google Scholar
  • 14  Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet.70(2), 425–434 (2002). Crossref, MedlineGoogle Scholar
  • 15  Demitrack MA, Dale JK, Straus SE et al.: Evidence for impaired activation of the hypothalamic–pituitary–adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab.73(6), 1224–1234 (1991). Crossref, Medline, CASGoogle Scholar
  • 16  Scott LV, Medbak S, Dinan TG: Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr. Scand.97(6), 450–457 (1998). Crossref, Medline, CASGoogle Scholar
  • 17  Cleare AJ, Miell J, Heap E et al.: Hypothalamic–pituitary–adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J. Clin. Endocrinol. Metab.86, 3545–3554 (2001).Crossref, Medline, CASGoogle Scholar
  • 18  Scott LV, Medbak S, Dinan TG: The low dose ACTH test in chronic fatigue syndrome and in health. Clin. Endocrinol. 48, 733–737 (1998).Crossref, Medline, CASGoogle Scholar
  • 19  Hudson M, Cleare AJ: The 1 µg short Synacthen test in chronic fatigue syndrome. Clin. Endocrinol.51, 625–630 (1999).Crossref, Medline, CASGoogle Scholar
  • 20  Tsigos C, Chrousos GP: Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res.53, 865–871 (2002).Crossref, MedlineGoogle Scholar
  • 21  Rajeevan MS, Smith AK, Dimulescu I, Vernon SD, Heim C, Reeves WC: Association of polymorphisms and haplotypes in the glucocorticoid receptor with chronic fatigue syndrome. American Society of Human Genetics, Salt Lake City, USA, 1926 (2005).Google Scholar
  • 22  Shih JC, Thompson RF: Monoamine oxidase in neuropsychiatry and behavior. Am. J. Hum. Genet.65(3), 593–598 (1995). Crossref, MedlineGoogle Scholar
  • 23  Fan J, Fossella J, Sommer T, Wu Y, Posner MI: Mapping the genetic variation of executive attention onto brain activity. PNAS100, 7406–7411 (2003).Crossref, Medline, CASGoogle Scholar
  • 24  Narita M, Nishigami N, Narita N et al.: Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem. Biophys. Res. Commun. 311 (2), 264–266 (2003).Crossref, MedlineGoogle Scholar
  • 25  Lin S, Jiang S, Wu X et al.: Association analysis between mood disorder and monoamine oxidase gene. Am. J. Med. Genet.96, 890–891 (2000).Crossref, MedlineGoogle Scholar
  • 26  Schulze TG, Muller DJ, Krauss H et al.: Association between a functional polymorphism in the monoamineoxidase A gene promoter and major depressive disorder. Am. J. Med .Genet.96, 801–803 (2000).Crossref, Medline, CASGoogle Scholar
  • 27  Du L, Bakish D, Ravindran A, Hrdina PD: MAOA gene polymorphisms are associated with major depression and sleep disturbance in males. Neuroreport15(13), 2097–2101 (2004).Crossref, Medline, CASGoogle Scholar
  • 28  Gutierrez B, Arias B, Gasto C et al.: Association analysis between a functional polymorphism in the monoamine oxidase A gene promoter and severe mood disorders. Psychiatr. Genet.14(4), 203–208 (2004).Crossref, MedlineGoogle Scholar

Websites

  • 101  HAPLO.STAT. http://mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfmGoogle Scholar